tiprankstipranks
TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M
The Fly

TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M

Preliminary Fourth Quarter and Full Year 2024 Updates: BRIUMVI U.S. net product revenue expected to be $103.6M and $310M for the fourth quarter and full year of 2024, respectively; Year-end 2024 cash position of approximately $310M

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles